Chemotherapy-induced Nausea and Vomiting
📧 Sign up to get email alerts when something new happens for Chemotherapy-induced Nausea and Vomiting.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2012-06-15FDA Approved: ONDANSETRON — Original Application (JVET PHARMACEUTICALS LLC)
FDA approved a generic ondansetron product from JVET Pharmaceuticals LLC under the Original Application, authorizing its marketing.
-
FDA approval · 2012-04-30FDA Approved: ONDANSETRON — Supplemental Application (West-Ward Pharmaceuticals Corp)
FDA approved a supplemental application for ondansetron from West-Ward Pharmaceuticals Corp under ANDA076781. This action grants regulatory …
-
FDA approval · 2012-04-30FDA Approved: ONDANSETRON — Supplemental Application (West-Ward Pharmaceuticals Corp)
The FDA approved a supplemental application for ondansetron submitted by West-Ward Pharmaceuticals Corp under ANDA076780, authorizing change…
-
FDA approval · 2012-04-27FDA Approved: ONDANSETRON — Supplemental Application (AvPAK)
FDA approves a supplemental application for ondansetron from AvPAK under an ANDA. This action updates the labeling/approval status of this g…
-
CLINICAL_TRIALS trial_result · 2012-04-24Clinical Trial Update: Efficacy and Safety Evaluation of Carbamazepine for Prevention of Chemotherapy-induced Nausea and Vomiting [Phase 2]
Phase 2 clinical trial evaluating carbamazepine for prevention of chemotherapy-induced nausea and vomiting, assessing its efficacy and safet…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2012-04-18FDA Approved: GRANISETRON HYDROCHLORIDE — Supplemental Application (Mylan Institutional LLC)
The FDA approved a supplemental application for granisetron hydrochloride from Mylan Institutional LLC, enabling its continued marketing as …
-
FDA approval · 2012-04-18FDA Approved: GRANISETRON HYDROCHLORIDE — Supplemental Application (Mylan Institutional LLC)
FDA approved a supplemental application for granisetron hydrochloride (generic) from Mylan Institutional LLC. This action updates the produc…
-
CLINICAL_TRIALS trial_result · 2012-04-16Clinical Trial Update: Bioequivalence Study of Ondansetron Tablets USP 8 mg Under Fasting Condition [Phase 1]
This update reports the completion of a Phase 1 bioequivalence study of Ondansetron 8 mg tablets under fasting conditions.
-
FDA approval · 2012-03-08FDA Approved: METOCLOPRAMIDE — Supplemental Application (Ipca Laboratories Limited)
FDA approved a supplemental application for metoclopramide from Ipca Laboratories Limited.
-
FDA approval · 2012-02-17FDA Approved: ONDANSETRON HYDROCHLORIDE — Supplemental Application (Hikma Pharmaceuticals USA Inc.)
FDA approved a supplemental application for ondansetron hydrochloride from Hikma Pharmaceuticals USA Inc., resulting in the approval of a ge…
-
FDA approval · 2012-02-13FDA Approved: ONDANSETRON — Supplemental Application (Dr. Reddy's Laboratories Limited)
FDA approved Dr. Reddy's Laboratories Limited's supplemental application for ondansetron hydrochloride (generic ondansetron) under ANDA 0761…
-
FDA approval · 2011-12-07FDA Approved: GRANISETRON HYDROCHLORIDE — Supplemental Application (Natco Pharma Limited)
The FDA approved a supplemental application for granisetron hydrochloride from Natco Pharma Limited.
-
CLINICAL_TRIALS trial_result · 2011-11-03Clinical Trial Update: Aprepitant and Fosaprepitant Time-on-Target PET (Positron Emission Tomography) Study (0869-183) [Phase 1]
This Phase 1 clinical trial evaluating time-on-target PET imaging for aprepitant and fosaprepitant in chemotherapy-induced nausea and vomiti…
-
FDA approval · 2011-10-17FDA Approved: ONDANSETRON HYDROCHLORIDE — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental application for ondansetron hydrochloride API from Aurobindo Pharma Limited.
-
FDA approval · 2011-09-30FDA Approved: ONDANSETRON — Supplemental Application (AvKARE)
FDA approved a supplemental application for AvKARE's ondansetron, confirming continued approval to produce and supply the drug.
-
CLINICAL_TRIALS trial_result · 2011-09-27Clinical Trial Update: Aprepitant/MK0869 for Prevention of Chemotherapy Induced Nausea and Vomiting Associated With Cisplatin (0869-169)(COMPLETED) [Phase 3]
Phase 3 trial update of aprepitant (MK0869) for prevention of chemotherapy-induced nausea and vomiting in cisplatin-treated patients; trial …
-
FDA approval · 2011-09-23FDA Approved: SANCUSO — Supplemental Application (Cumberland Pharmaceuticals Inc.)
FDA approved a supplemental application for SANCUSO (granisetron) from Cumberland Pharmaceuticals Inc., updating the product's labeling.
-
CLINICAL_TRIALS trial_result · 2011-08-10Clinical Trial Update: Phase II Trial of Aprepitant & Palonosetron for CINV Prevention w FOLFOX [Phase 2]
Phase II trial evaluating the combination of aprepitant and palonosetron for prevention of chemotherapy-induced nausea and vomiting in color…
-
CLINICAL_TRIALS trial_result · 2011-07-07Clinical Trial Update: Comparative Study of Palonosetron With Granisetron as a Control in Patients Receiving Highly Emetogenic Chemotherapy [Phase 3]
Phase 3 clinical trial comparing palonosetron with granisetron for prevention of chemotherapy-induced nausea and vomiting in patients receiv…
-
CLINICAL_TRIALS trial_result · 2011-06-21Clinical Trial Update: Phase 2 Study of Efficacy, Tolerability, and Safety of Intranasal Granisetron for Chemo-Induced Nausea and Vomiting [Phase 2]
Phase 2 study evaluating the efficacy, tolerability, and safety of intranasal granisetron for preventing chemotherapy-induced nausea and vom…
-
FDA approval · 2011-04-01FDA Approved: GRANISETRON HYDROCHLORIDE — Supplemental Application (Mylan Institutional LLC)
FDA approved a supplemental application for Granisetron Hydrochloride (generic) filed by Mylan Institutional LLC. This action confirms appro…
-
FDA approval · 2011-02-25FDA Approved: ONDANSETRON — Supplemental Application (Fresenius Kabi USA, LLC)
FDA approved a supplemental application for ondansetron hydrochloride (generic ondansetron) by Fresenius Kabi USA, LLC.
-
CLINICAL_TRIALS trial_result · 2011-02-03Clinical Trial Update: Palonosetron Versus Ondansetron for the Prevention of Nausea and Vomiting [Phase 2]
A Phase 2 randomized trial compared palonosetron to ondansetron for the prevention of chemotherapy-induced nausea and vomiting in patients w…
-
FDA approval · 2011-01-31FDA Approved: ONDANSETRON — Supplemental Application (West-Ward Pharmaceuticals Corp)
FDA approved a supplemental application for ondansetron submitted by West-Ward Pharmaceuticals Corp.
-
FDA approval · 2011-01-31FDA Approved: ONDANSETRON — Original Application (AvPAK)
FDA approved Ondansetron under AvPAK's original generic application (ANDA 091483) to prevent nausea and vomiting associated with chemotherap…